Increased baseline <scp>RUNX</scp>2, caspase 3 and p21 gene expressions in the peripheral blood of disease‐modifying anti‐rheumatic drug‐naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy

Tchetina, Elena V.; Демидова, Н. В.; Маркова, Г. А.; Таскина, Е. А.; Глухова, С. И.; Karateev, D.

doi:10.1111/1756-185x.13131

Cited by 11 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in accordance with [17] who suggested the important role of this osteoclastogenic factor in promoting osteoclasts formation and bone resorption, following MTX-chemotherapy. Moreover, [22] demonstrated that, MTX could increase osteoclasts density and reduce osteogenic differentiation; accompanied by reduction in mRNA expression of osteogenic factors. Similarly, [17] observed, upregulation of RANKL/OPG ratio and proinflammatory cytokines such as TNF-α, IL-1 and IL-6 in MTX-treated rats.…”

Section: Discussionmentioning

confidence: 99%

Comparative Histological Study on the Protective Effect of Folinic Acid versus Fish Oil on the Growing Bone of Methotrexate-Treated Young Rats

Bassiouny

Amin

Ibrahim

et al. 2019

Egyptian Journal of Histology

View full text Add to dashboard Cite

Background: Folinic acid (FA) is used to reduce Methotrexate (MTX) toxicity during treatment of childhood acute lymphoblastic leukemia (ALL). However, FA has been shown to reduce MTX treatment efficacy and cure rates of ALL. Recent studies suggested that fish oil (FO) supplementation may protect bone during MTX chemotherapy. Aim of Work: to compare the protective effect of FA versus FO on the growing bone of MTX-treated young rats monitored by histological, immunohistochemical, morphometric and laboratory methods. Materials and Methods: Forty two, 6 weeks-old-male albino rats were divided into: group I (control), group II (MTXtreated), group III (MTX and FA-treated) and group IV (MTX and FO-treated). MTX was injected subcutaneously, once daily for 5 consecutive days, 0.65 mg/kg, followed by 9 days of rest, then 1.3 mg/kg twice weekly for 4 weeks. FA was injected intraperitoneally, 6 hours after each dose of MTX, 0.87 mg/kg, then1.3 mg/kg twice weekly. FO was given orally daily for 6 weeks, 0.5 ml/100 gm. Left knee joints were processed for measuring RANKL/ OPG ratio (Receptor Activator of Nuclear factor Kapp-B Ligand/ Osteoprotegerin). Right knee joint sections were stained with H&E, Masson's Trichrome and immunohistochemical staining for Caspase-3. Morphometric measurements and statistical analysis were done. Results: MTX-treated group sections revealed disruption in the growth plate structure with subsequent reduction in endochondral bone formation. Supplementation with FA and FO preserved growth plate integrity and bone formation. Conclusion: Fish oil showed better effect than Folinic acid in ameliorating growth plate disruption and retarded bone formation encountered during MTX chemotherapy in young rats.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Histological Study on the Protective Effect of Folinic Acid versus Fish Oil on the Growing Bone of Methotrexate-Treated Young Rats

Bassiouny

Amin

Ibrahim

et al. 2019

Egyptian Journal of Histology

View full text Add to dashboard Cite

show abstract

“…The same study also showed there was a significant positive correlation between caspase‐3 and Psoriasis Area and Severity Index score . In another case‐control study by Tchetina et al including 40 patients with rheumatoid arthritis, it was reported that runt‐related transcription factor 2, caspase‐3 and p21 gene levels were decreased after treatment and it was asserted that they could be used in the prediction of treatment response …”

Section: Discussionmentioning

confidence: 99%

Low levels of pannexin‐1 in Behçet’s syndrome

et al. 2019

View full text Add to dashboard Cite

Objective Behçet's syndrome (BS) is a chronic, multisystemic and inflammatory syndrome. In our study, we aimed to compare the initiator, effector and inflammatory caspases and pannexin channel protein, which is thought to have an activity in inflammation, in the inflammatory process of BS, with healthy subjects, to investigate their level in patients and their relationship with the clinical findings. Method Forty‐six patients who were under follow‐up for BS in the Sivas Cumhuriyet University Medical Faculty Department of Internal Diseases, Rheumatology Unit, between January 2017 and June 2017 and 44 healthy controls (HC) who did not have any rheumatic, systemic or metabolic diseases, were enrolled in this study. Results The mean serum pannexin‐1 level was 6.36 (4.21‐527.2) pg/mL in the BS group and 255.8 (5.38‐2000) pg/mL in the HC group. Serum pannexin‐1 levels were statistically significantly lower in the BS group (P < 0.0001). The measured mean serum caspase‐3 level was 12.04 (11.25‐43.69) pg/mL in the group with BS and 12.1 (11.19‐484.3) pg/mL in the HC group (P = 0.143), mean serum caspase‐9 level was 22 (5.14‐29.33) pg/mL in the BS group and 22.01 (11.23‐850) pg/mL in the HC group (P = 0.593), mean serum caspase‐14 level was 6 (5.2‐8.21) pg/mL in the BS group and 6.15 (5.7‐353) pg/mL in the HC group (P = 0.053). Conclusion Comparison of serum caspase‐3, caspase‐9 and caspase‐14 levels in subjects with BS and in the HC group did not reveal any statistically significant differences. On the other hand, serum pannexin‐1 levels were statistically significantly lower in the BS group.

show abstract

“…Для этого необходимо провести исследование на когорте больных, которые ранее не получали данный препарат, определить экспрессию генов, обуславливающих воспаление, болевой синдром и/или разрушение суставов до и после терапии. Корреляционный анализ клинических данных больных после терапии с уровнем экспрессии генов данной когорты до терапии позволит выявить те гены, чья базальная экспрессия может свидетельствовать об эффективности применения терапевтического средства [152]. В дальнейшем, терапию данным препаратом следует проводить тем пациентам, у которых базальная экспрессия генов изменена соответствующим образом.…”

Section: анализ экспрессии генов в крови как инструмент персонифицироunclassified

Upcoming value of gene expression analysis in rheumatology

Четина

Маркова

2018

BIOMED KHIM

View full text Add to dashboard Cite

Ревматические заболевания (РЗ) -это хронические воспалительные заболевания неизвестной этиологии, в ходе которых нарушаются функции сигнальных путей иммунной системы. Это сопровождается поражением ряда других тканей, болью и разрушением суставов. Современная терапия направлена на коррекцию патофизиологических и биохимических механизмов, ответственных за клиническую манифестацию заболевания. В связи с гетерогенностью больных РЗ существует необходимость персонифицированного лечения, выбор которого осложняется тем, что не все больные одинаково отвечают на терапию. Анализ экспрессии генов представляет инструмент для контроля заболевания и персонализации терапии больных с целью подавления воспаления и боли, а также замедления разрушения суставов.Ключевые слова: ревматические заболевания; ревматоидный артрит; экспрессия генов; провоспалительные цитокины; протеазы; боль

show abstract

Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease‐modifying anti‐rheumatic drug‐naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy

Abstract: Our results suggest that the expressions of MMP-9 and ULK1 might be associated with disease activity. Increased baseline gene expressions of RUNX2, p21 and caspase 3 in the peripheral blood might predict better responses to MTX therapy.

Cited by 11 publications

References 50 publications

Comparative Histological Study on the Protective Effect of Folinic Acid versus Fish Oil on the Growing Bone of Methotrexate-Treated Young Rats

Comparative Histological Study on the Protective Effect of Folinic Acid versus Fish Oil on the Growing Bone of Methotrexate-Treated Young Rats

Low levels of pannexin‐1 in Behçet’s syndrome

Upcoming value of gene expression analysis in rheumatology

Contact Info

Product

Resources

About